Blog
RSS FeedPosted by Michael Wonder on 29 May 2024
Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments
28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...
Posted by Michael Wonder on 29 May 2024
Dabrafenib mesylate in combination with trametinib dimethyl sulphoxide for the treatment of children and adolescents with BRAF V600E mutation positive glioma
29 May 2024 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Finlee) in combination with ...
Posted by Michael Wonder on 29 May 2024
Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy
29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...
Posted by Michael Wonder on 25 May 2024
Issues, challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review
25 May 2024 - There are significant challenges when obtaining clinical and economic evidence for health technology assessments of rare diseases. ...
Posted by Michael Wonder on 24 May 2024
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...
Posted by Michael Wonder on 22 May 2024
Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex
22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of ...
Posted by Michael Wonder on 16 May 2024
Acceptability of using real world data to estimate relative treatment effects in health technology assessments: barriers and future steps
15 May 2024 - Evidence about the comparative effects of new treatments is typically collected in randomised controlled trials (RCTs). In ...
Posted by Michael Wonder on 16 May 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (final guidance)
15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib ...
Posted by Michael Wonder on 15 May 2024
Atogepant monohydrate for the prevention of migraine
15 May 2024 - NICE has published final evidence-based recommendations on atogepant monohydrate (Aquipta) for preventing migraine in adults. ...
Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...
Posted by Michael Wonder on 08 May 2024
Selinexor with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more treatments
8 May 2024 - NICE has published evidence-based recommendations on the use of selinexor (Nexpovio) in combination with dexamethasone for ...
Posted by Michael Wonder on 03 May 2024
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
3 May 2024 - Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE ...
Posted by Michael Wonder on 03 May 2024
NHS rolls out ‘life-changing’ treatment for thousands with sickle cell disease
3 May 2024 - Thousands of patients with sickle cell disorder are to be offered a new “life-changing” treatment on ...
Posted by Michael Wonder on 01 May 2024
Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 May 2024
Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...